KYORIN Pharmaceutical Co., Ltd.
Supplementary Materials for Q2 (Interim) Results for the Fiscal Year Ending March 2027
Net sales were 57,489 million yen, a year-over-year decline. Domestic new pharmaceuticals grew due to Beovar and others, but decreases resulted from drug price revisions and the entry of generics. Overseas new pharmaceuticals saw a decline due to revenue reversals, while the generics segment contributed increased revenue. Interim net loss attributable to owners of the parent was -1,566 million yen. Full-year forecasts have been revised. Dividend forecast remains unchanged.
Key Figures
- Net Sales: 57,489 million yen → 57,489 million yen (YoY -2.1%)
- Operating Income: 306 million yen → 306 million yen (significant decrease Year-over-Year)
- Net Income Attributable to Owners of Parent (Interim): -1,566 million yen (Prior interim -1,566 million yen)
AI要約
Performance Overview
Consolidated net sales for Q2 of the fiscal year ending March 2027 declined from 58,700 million yen to 57,500 million yen. Domestic new pharmaceuticals showed growth led by Beovar, but overall decreased due to drug price revisions and the entry of generic Desalex. Overseas new pharmaceuticals experienced a revenue rebound decline related to gatifloxacin. The generics segment contributed increased revenue. Operating income fell to the 300 million yen range and ordinary income also decreased. Interim net income turned negative. The disclosed full-year forecast has been revised. The dividend forecast remains unchanged.
Outlook and Key Risks
Considering upfront license payments and extraordinary losses associated with business transfers, the full-year forecast has been revised. Attention should be paid to structural changes accompanying the transfer of the generics business and the ongoing impact of the domestic drug pricing system. Overseas expansion of new pharmaceuticals and contributions from generics are expected to be drivers for earnings recovery.
KYORIN Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
